Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Qrons
Qrons Overview
Qrons is a biotechnology company dedicated to developing biotech products, treatments and technologies that create a platform to combat neuronal diseases. Its approach seeks to marshal and leverage the remarkable advances made in the fields of artificial intelligence (AI), machine learning (ML), molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases.
The company has two product candidates for treating traumatic brain injuries, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material. QS100 is an injury-specific, 3D-printable, implantable MSC-synthetic hydrogel for treating penetrating brain injuries. QS200 is an injectable MSC-synthetic hydrogel for the treatment of concussions.
The company conducts its research in Israel under service agreements with Ariel University and has an ongoing sponsored research agreement with Dartmouth College.
Qrons Announces the Addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board to Beef up its Team, as Part of its New Sepsis Research Program
#Management Changes #Expand
Aug 23, 2023
finance.yahoo.com
Qrons Announces Launch of its New Website in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
#Customers #Investment
Aug 14, 2023
finance.yahoo.com
Qrons Announces the Filing of a Provisional Patent Application in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
#Partners #Investment
Jul 20, 2023
finance.yahoo.com
Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and Traumatic Brain Injuries
undefined
Mar 22, 2023
finance.yahoo.com
Qrons files U.S. National Phase of its Patent Application in Furtherance of its QS200 Product Candidate for Therapeutic Polypseudorotaxane Hydrogels
Qrons Announces the Addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board to Beef up its Team, as Part of its New Sepsis Research Program
#Management Changes #Expand
Aug 23, 2023
finance.yahoo.com
Qrons Announces Launch of its New Website in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
#Customers #Investment
Aug 14, 2023
finance.yahoo.com
Qrons Announces the Filing of a Provisional Patent Application in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
#Partners #Investment
Jul 20, 2023
finance.yahoo.com
Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and Traumatic Brain Injuries
undefined
Mar 22, 2023
finance.yahoo.com
Qrons files U.S. National Phase of its Patent Application in Furtherance of its QS200 Product Candidate for Therapeutic Polypseudorotaxane Hydrogels
undefined
View other companies you might be interested in
Qrons Team
No Data, yet.
Sorry, no content found under this section.
View other companies you might be interested in
Connect with
What is the reason for connecting? *
Your company *
Company website (recommended)
Please enter a valid website
Your organization type *
Please enter a valid organization type
Your position *
Add invitation message
0/300
Sending invitation...
Invitation sent
You will be able to start a conversation once [Name] accepts it.